— Research Library
Literature reviews on longevity, metabolic health, growth hormone axis, and regenerative compounds. For research use only.
— Featured overview
Most research peptides have never been near a regulatory filing. Sermorelin was an approved drug in the 1980s — and that history is exactly why
— All research posts
Most research peptides have never been near a regulatory filing. Sermorelin was an approved drug in the 1980s — and that history is exactly why
If you’ve researched growth-hormone secretagogues at all, you’ve hit this pairing first. It’s the standard starting stack for a reason. Two Receptors, One Additive Effect
Ask any experienced researcher what pairs with BPC-157, and TB-500 comes up first. It earns that spot through a mechanism entirely its own. Faster Repair,
Cells make antioxidants for a living. One stands above the rest. Glutathione is often called the master antioxidant — and for good reason. It is
Most research peptides have never been near a Phase 3 trial. Thymosin Alpha-1 has. Its pharmaceutical form is approved in multiple countries, and its clinical
Most research peptides never leave the lab. SS-31 did more than that. In September 2025, its pharmaceutical form — elamipretide — became the first mitochondria-targeted
KPV is only three amino acids long. Yet published research shows it carries much of the anti-inflammatory power of a far larger hormone. It does
